When Antibiotics Stop Working: New Hope from Viruses That ‘Eat’ Bacteria

Adrian Mercer

Antibiotics are among the most important achievements of modern medicine. But as bacteria increasingly develop resistance to these drugs, even common infections are becoming more difficult to treat. Antimicrobial resistance is now considered one of the major threats to global health.

Amid this growing crisis, medical science is revisiting a treatment method that is more than a century old but has regained scientific attention. It is called bacteriophage, or phage, therapy. Phages are not viruses that infect humans. They infect and destroy specific bacteria.

The scientific principle is fascinating. Antibiotics may affect several types of bacteria in the body, while phages generally target particular bacteria. This raises the possibility of destroying disease-causing bacteria while causing less disruption to beneficial microorganisms.

A phage attaches itself to the surface of a bacterium and injects its genetic material inside. It then uses the bacterium’s own biological machinery to produce new phages. Eventually, the bacterial cell ruptures, releasing new phages that can attack other target bacteria.

The technology is not entirely new. Phage therapy has been used for decades in parts of Eastern Europe. Its importance declined after the rapid development of antibiotics, but the rise of multidrug-resistant infections has brought it back to the centre of scientific research.

Researchers are particularly interested in phage therapy for complicated infections in which conventional antibiotics no longer work effectively. Studies are examining its potential in lung, wound, bone and hospital-acquired infections. Some research also suggests that combining phages with antibiotics may improve treatment effectiveness.

Phage therapy, however, cannot yet be regarded as a complete alternative to antibiotics. Clinical trials are continuing in several countries. More evidence is needed on effectiveness, appropriate dosage, manufacturing quality, immune responses and long-term safety.

The greatest strength of phage therapy is also one of its biggest challenges. A single phage does not kill every bacterium. Doctors must first identify the bacterium causing an infection and then find a phage capable of attacking it. If the wrong phage is selected, the treatment may have little or no effect.

For this reason, future phage therapy could become closely linked to personalized medicine. A patient’s sample may need to be tested, the bacterium isolated and its biological and genetic characteristics identified before an effective phage can be selected.

Artificial intelligence and genomics are also becoming part of this emerging field. Researchers are exploring ways to analyze large amounts of genetic data from phages and bacteria to predict more quickly which phage is likely to work against a particular bacterial strain.

Hospitals may eventually maintain their own collections of phages effective against locally common drug-resistant bacteria. Once an infection is identified, an appropriate phage could potentially be selected from such a library to develop a more personalized treatment.

There is another challenge. Just as bacteria can develop resistance to antibiotics, they can also evolve resistance to phages. Researchers are therefore studying combinations of several phages, known as phage cocktails, as well as strategies that combine phages with antibiotics.

The issue is particularly relevant to Nepal. The inappropriate use of antibiotics, failure to complete prescribed treatment, unnecessary use against viral infections and excessive use of antimicrobial drugs in both human medicine and animal production can accelerate the development of resistant bacteria.

Nepal has been expanding laboratory capacity for identifying bacteria and testing their sensitivity to antibiotics. Strong microbiology laboratories, genomic testing and infection-surveillance systems would also be essential if targeted therapies such as phages are to become practical in the future.

The promise of phage therapy, however, should not become an excuse for careless antibiotic use today. Developing and approving new treatments can take years. The immediate priority must therefore remain protecting the effectiveness of the antibiotics already available.

Antibiotics should not be taken without medical advice. Patients should complete the prescribed dose and duration, avoid unnecessary antibiotics for viral infections and support responsible antimicrobial use in hospitals, communities and animal health.

Phage therapy is not a miracle cure. But it represents an important new possibility in medical science. Instead of relying only on new chemical drugs, scientists are attempting to use viruses that nature itself has employed for billions of years to control bacterial populations.

The antibiotic era is not over. But the future of infection treatment may no longer depend on antibiotics alone. Phages, genomics, artificial intelligence and personalized medicine could together shape a new generation of therapies that are more targeted, precise and scientifically sophisticated.